Erratum to: Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis (Thromb Haemost (2015), 113, (719-727), 10.1160/TH14-06-0547);Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis

Thrombosis and Haemostasis

Volumn 113, Issue 4, 2015, Pages 719-727

  Parasrampuria, Dolly A ^a   Marbury, Thomas ^b   Matsushima, Nobuko ^c   Chen, Shuquan ^a   Wickremasingha, Prachi K ^d   He, Ling ^a   Dishy, Victor ^a   Brown, Karen S ^a  

^a DAIICHI SANKYO INC   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

^c DAIICHI SANKYO CO   (Japan)

^d Certified Consultant Pharmacists Inc   (United States)

Author keywords

Edoxaban; Elimination; Haemodialysis; Oral factor Xa inhibitor; Pharmacokinetics

Indexed keywords

EDOXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATRIAL FIBRILLATION; BLOOD FLOW; BODY MASS; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VENOUS THROMBOEMBOLISM; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG MONITORING; HALF LIFE TIME; KIDNEY FAILURE, CHRONIC; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FACTOR XA INHIBITORS; FEMALE; HALF-LIFE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; PYRIDINES; RENAL DIALYSIS; THIAZOLES; TREATMENT OUTCOME;

EID: 84926072217     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH17040001     Document Type: Erratum

References (14)

1. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008; 4: 1065-1074.
2. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009; 65: 757-773.
3. U. S. Dept of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER). Guidance for industry. Pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. Draft guidance. http://www. fda. gov/downloads/Drugs/. . . /Guidances/UCM204959. pdf. Published March 2010 [cited 2013 April 30].
4. Furugohri T, Isobe K, Honda Y, et al. Du-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008; 6: 1542-1549.
5. Hokusai VTE Investigators, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
6. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
7. Matsushima N, Lee F, Sato T, et al. Bioavailability and safety of the factor xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharm in Drug Dev 2013; 2: 358-366.
8. Bathala MS, Masumoto H, Oguma T, et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor xa inhibitor, in humans. Drug Metab Dispos 2012; 40: 2250-2255.
9. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: I4-I8.
10. Marinigh R, Lip GY, Fiotti N, et al. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis: Implications for thromboprophylaxis. J Am Coll Cardiol 2010; 56: 827-837.
11. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278-285.
12. Ridout G, de la Motte S, Niemczyk S, et al. Effect of renal function on edoxaban pharmacokinetics (PK) and on population PK/PD model. J Clin Pharmacol 2009; 49: 1124. Abstract 1144.
13. Salazar DE, Mendell J, Kastrissios H, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012; 107: 925-936.
14. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50: 743-753.